James Hamrick, MD, senior medical director at Flatiron Health, discusses how to turn patient feedback on what value means to them into actionable information.
James Hamrick, MD, senior medical director at Flatiron Health, discusses how to turn patient feedback on what value means to them into actionable information.
Transcript
Once you identify what is of value to patients, how do you turn this into actionable information that can be addressed by both patients and providers?
Once you begin to understand what brings value to patients, and let’s use the example of transparency with lab results, it’s really important for patients to be able to have access to their lab results because that gives them actionable information for themselves. If I’m a cancer patient on chemotherapy and I can see whether my white count is trending down, that’s going to help me know how to behave. It’s going to help me react to something like a fever or an illness that’s happened to me.
Once you have that data and you have the understanding of what the patients need from it, you have to build it in a user-friendly way. So, we think about ways we can have our design experts design interactions between the patients and their lab results in the patient portal that makes sense for patients so that you can deliver a lot of data to the patient, really quickly in an effective way for them to understand it and know what they should do or who they should contact for next steps.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More